# A Study Comparing DMSB01 and Rejuran® for Temporary Crow's Feet Lines Improvement

> **NCT06402058** · NA · NOT_YET_RECRUITING · sponsor: **Samyang Biopharmaceuticals Corporation** · enrollment: 60 (estimated)

## Conditions studied

- Crow's Feet Lines

## Interventions

- **DEVICE:** DMSB01
- **DEVICE:** Rejuran®

## Key facts

- **NCT ID:** NCT06402058
- **Lead sponsor:** Samyang Biopharmaceuticals Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-06-10
- **Primary completion:** 2025-01-31
- **Final completion:** 2025-04-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06402058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06402058, "A Study Comparing DMSB01 and Rejuran® for Temporary Crow's Feet Lines Improvement". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06402058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*